Stockreport

MULTIMEDIA UPDATE - Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

Albireo Pharma, Inc.  (ALBO) 
Last albireo pharma, inc. earnings: 3/2 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.albireopharma.com/investor-relations
PDF – Only once-daily drug indicated for the treatment of pruritus in PFIC – – Commercial launch of Bylvay immediate; available for prescription in the coming days – – Rar [Read more]